Human Longevity, Celgene Cellular Therapeutics Ink Deal for Placental Cell Population | GenomeWeb

NEW YORK (GenomeWeb) – Human Longevity today announced an agreement to license, develop, and co-promote Celgene Cellular Therapeutics' placental cell population, PSC-100.

As part of the deal, CCT, a Celgene company, has made an equity investment of an undisclosed amount into La Jolla, Calif.-based Human Longevity. Other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.